Daughaday WH, Rotwein P. Insulin-like growth factors I and II. Peptide, messenger ribonucleic acid and gene structures, serum, and tissue concentrations. Endocr Rev. 1989; 10:68-91.
Ullrich A, Gray A, Tam AW, Yang-Feng T, Tsubokawa M, Collins C, et al. Insulin-like growth factor I receptor primary structure: comparison with insulin receptor suggests structural determinants that define functional specificity. EMBO J. 1986; 5:2503-12.
Myers MG Jr, Sun XJ, Cheatham B, Jachna BR, Glasheen EM, Backer JM, et al. IRS-1 is a common element in insulin and insulin-like growth factor-I signaling to the phosphatidylinositol 3′-kinase. Endocrinology. 1993; 132:1421-30.
Adamo M, Roberts CT Jr, LeRoith D. How distinct are the insulin and insulin-like growth factor I signalling systems? Biofactors. 1992; 3:151-7.
Soos MA, Field CE, Siddle K. Purified hybrid insulin/insulin-like growth factor-I receptors bind insulin-like growth factor-I, but not insulin, with high affinity. Biochem J. 1993; 290:419-26.
Moxham CP, Duronio V, Jacobs S. Insulin-like growth factor I receptor β subunit heterogeneity. Evidence for hybrid tetramers composed of insulin-like growth factor I and insulin receptor heterodimers. J Biol Chem. 1989; 264:13238-44.
Phillips LS, Harp JB, Goldstein S, Klein J, Pao CI. Regulation and action of insulin-like growth factors at the cellular level. Proc Nutr Soc. 1990; 49:451-8.
Guler HP, Schmid C, Zapf J, Froesch ER. Effects of recombinant insulin-like growth factor I on insulin secretion and renal function in normal human subjects. Proc Natl Acad Sci U S A. 1989; 86:2868-72.
Bach MA, Chin E, Bondy CA. The effects of recombinant insulin-like growth factor I (IGF-I) on growth hormone, IGF-II, IGF binding protein and blood glucose levels in normal and diabetic adolescents. Ped Res. 1993; 33:190.
Rennert NJ, Caprio S, Sherwin RS. Insulin-like growth factor I inhibits glucose-stimulated insulin secretion but does not impair glucose metabolism in normal humans. J Clin Endocrinol Metab. 1993; 76:804-6.
Zenobi PD, Jaeggi-Groisman SE, Riesen WF, Roder ME, Froesch ER. Insulin-like growth factor-I improves glucose and lipid metabolism in type 2 diabetes mellitus. J Clin Invest. 1992; 90:2234-41.
McCusker RH, Clemmons DR. The insulin-like growth factor binding proteins: structure and biological functions. In: Schofield PN, ed. The Insulinlike Growth Factors: Structure and Biological Functions. New York: Oxford University Press; 1992:110-50.
Baxter R. Circulating binding proteins for the insulinlike growth factors. Trends in Endocrinology and Metabolism. 1993; 4:91-6.
Chin E, Bondy CA. IGF system gene expression in the human kidney. J Clin Endocrinol Metab. 1992; 75:962-8.
Zhou J, Bondy CA. Anatomy of the human ovarian insulin-like growth factor system. Biol Reprod. 1993; 48:467-82.
Mohan S, Jennings JC, Linkhart TA, Baylink DJ. Primary structure of human skeletal growth factor: homology with insulin-like growth factor-II. Biochim Biophys Acta.1988; 966:44-55.
Iranmanesh A, Lizarralde G, Veldhuis JD. Age and relative adiposity are specific negative determinants of the frequency and amplitude of growth hormone (GH) secretory bursts and the half-life of endogenous GH in healthy men. J Clin Endocrinol Metab. 1993; 73: 1081-8.
Quin JD, Fisher BM, Paterson KR, Inoue A, Beastall GH, MacCuish AC. Acute response to recombinant insulin-like growth factor I in a patient with Mendenhall's syndrome (Letter). N Engl J Med. 1990; 323:1425-6.
Schoenle EJ, Zenobi PD, Torresani T, Werder EA, Zachmann M, Froesch ER. Recombinant human insulin-like growth factor I (rhIGF I) reduces hyperglycaemia in patients with extreme insulin resistance. Diabetologia. 1991; 34:675-9.
Morrow L, O'Brien M, Moller D, Flier J, Moses A. Recombinant human IGF-I reverses hyperglycemia and improves insulin sensitivity in severe insulin resistance (Abstract). Diabetes. 1993; 42(Suppl): 269.
Kuzuya H, Matsuura N, Sakamoto M, Makino H, Sakamoto Y, Kadowaki T, et al. Trial of insulinlike growth factor I therapy for patients with extreme insulin resistance syndromes. Diabetes. 1993; 42:696-705.
Laron Z, Pertzelan A, Karp M, Kowaldo-Silbergeld A, Daughaday WH. Administration of growth hormone to patients with familial dwarfism and high plasma immunoreactive growth hormone: measurement of sulfation factor, metabolic and linear growth response. J Clin Endocrinol Metab. 1971; 33:332-42.
Walker JL, Ginalska-Malinowska M, Romer T, Pucilowska JB, Underwood LE. Effects of the infusion of insulin-like growth factor I in a child with growth hormone insensitivity syndrome (Laron dwarfism). N Engl J Med. 1991; 324:1483-8.
Walker JL, Van Wyk JJ, Underwood LE. Stimulation of statural growth by recombinant insulin-like growth factor I in a child with growth hormone insensitivity syndrome (Laron-type). J Pediatr. 1992; 121:641-6.
Laron Z, Anin S, Klipper-Auerbach Y, Klinger B. Effects of insulin-like growth factor on linear growth, head circumference, and body fat in patients with Laron-type dwarfism. Lancet. 1992; 339:1258-61.
Backeljauw PF, Underwood LE, Miras M, Arriazu MC, Heinrich J, et al. Effects of prolonged IGF-I treatment in children with growth hormone insensitivity syndrome (GHIS). Presented at the Fourth Joint meeting of the Lawson Wilkins Pediatric Endocrine Society, 3-6 June 1993, San Francisco, California.
Underwood LE, D'Ercole AJ, Clemmons DR, Van Wyk JJ. Paracrine functions of somatomedins. Clin Endocrinol Metab. 1986; 15:59-78.
Green H, Morikawa M, Nixon T. A dual effector theory of growth hormone action. Differentiation. 1985; 29:195-8.
Ziegler TR, Young LS, Manson JM, Wilmore DW. Metabolic effects of recombinant human growth hormone in patients receiving parenteral nutrition. Ann Surg. 1988; 208:6-16.
Belcher HJ, Mercer D, Judkins KC, Shalaby S, Wise S, Marks V, et al. Biosynthetic human growth hormone in burned patients: a pilot study. Burns. 1989; 15:99-107.
Dahn MS, Lange MP, Jacobs LA. Insulin-like growth factor I production is inhibited in human sepsis. Arch Surg. 1988; 123:1409-14.
Maes M, Underwood LE, Ketelslegers JM. Low somatomedin-C in protein deficiency: relationship with changes in liver somatogenic and lactogenic binding sites. Mol Cell Endocrinol. 1984; 37:310-9.
Thissen JP, Davenport ML, Pucilowska JB, Miles MV, Underwood LE. Increased serum clearance and degradation of 125I-labeled IGF-I in protein-restricted rats. Am J Physiol. 1992; 262:E406-11.
Snyder DK, Clemmons DR, Underwood LE. Treatment of obese, diet-restricted subjects with growth hormone for 11 weeks: effects on anabolism, lipolysis, and body composition. J Clin Endocrinol Metab. 1988; 67:54-61.
Clemmons DR, Smith-Banks A, Underwood LE. Reversal of diet-induced catabolism by infusion of recombinant insulin-like growth factor-I in humans. J Clin Endocrinol Metab. 1992; 75:234-8.
Kupfer SR, Underwood LE, Baxter RC, Clemmons DR. Enhancement of the anabolic effects of growth hormone and insulin-like growth factor I by the use of both agents simultaneously. J Clin Invest. 1993; 91:391-6.
Baxter RC, Bayne ML, Cascieri MA. Structural determinants for binary and ternary complex formation between insulin-like growth factor-I (IGF-I) and IGF binding protein-3. J Biol Chem. 1992; 267: 60-5.
Hall K, Johansson BL, Povoa G, Thalme B. Serum levels of insulin-like growth factor (IGF) I, II and IGF binding protein in diabetic adolescents treated with continuous subcutaneous insulin infusion. J Intern Med. 1989; 225:273-8.
Winter RJ, Phillips LS, Klein MN, Traisman HS, Green OC. Somatomedin activity and diabetic control in children with insulin-dependent diabetes. Diabetes. 1979; 28:952-4.
Lanes R, Recker B, Fort P, Lifshitz F. Impaired somatomedin generation test in children with insulin-dependent diabetes mellitus. Diabetes. 1985; 34:156-60.
Press M, Tamborlane WV, Sherwin RS. Importance of raised growth hormone levels in mediating the metabolic derangements of diabetes. N Engl J Med. 1984; 310:810-5.
Guler HP, Zapf J, Froesch ER. Short-term metabolic effects of recombinant human insulin-like growth factor in healthy adults. N Engl J Med. 1987; 317:137-40.
Schalch DS, Turman NJ, Marcsisin V, Guler HP. Short-term metabolic effects of recombinant human insulin-like growth factor I (rhIGF-I) in type II diabetes mellitus. In: Spencer EM, ed. Modern Concepts of Insulin-like Growth Factors. New York: Elsevier; 1991:705-15.
Taylor SI, Kadowaki T, Kadowaki H, Accili D, Cama A, McKeon C. Mutations in insulin-receptor gene in insulin-resistant patients. Diabetes Care. 1990; 13:257-79.
Moller DE, Flier JS. Insulin-resistance—mechanisms, syndromes, and implications. N Engl J Med. 1991; 325:938-48.
Livingston N, Pollare T, Lithell H, Arner P. Characterisation of insulin-like growth factor I receptors in skeletal muscles of normal and insulin-resistant subjects. Diabetologia. 1988; 31:871-7.
Skarulis MC, Cochran C, Koller E. Effects of intravenous IGF-I on glucose metabolism in patients with extreme insulin resistance (Abstract). 76th Annual Endocrine Society Meeting. 1993:729.
Hone J, Skarulis MC, Roach P, Donaldson D, Cochran C, Eastman RC. IGF-I treatment of severely insulin-resistant child with short stature and diabetes mellitus (Abstract). 76th Annual Endocrine Society Meeting. 1993:1319.
Caro JF, Poulos J, Ittoop O, Pories WJ, Flickinger EG, Sinha MK. Insulin-like growth factor-I binding in hepatocytes from human liver, human hepatoma, and normal, regenerating, and fetal rat liver. J Clin Invest. 1988; 81:976-81.
Bolinder J, Lindblad A, Engfeldt P, Arner P. Studies of acute effects of insulin-like growth factors I and II in human fat cells. J Clin Endocrinol Metab. 1987; 65:732-7.